
Claims

1. A solid form of Compound 1 having the formula:



Compound 1, wherein the solid form is crystalline.

2. The solid form of claim 1, which is anhydrous.

3. The solid form of claim 1, which is hydrated or solvated.

4. The solid form of claim 1, which is a monohydrate.

5. The solid form of any one of claims 1-4, wherein the solid form has Form A, Form B, Form C, Form D, or Form E.

6. The solid form of claim 5, wherein the solid form has Form A.

7. The solid form of claim 6, wherein the solid form has at least one characteristic XRPD peak selected from about 4.7, about 9.3, about 13.9, about 15.8, about 18.6, about 19.0, about 21.5, and about 27.4 degrees 2-theta.

8. The solid form of claim 6, wherein the solid form has at least two characteristic XRPD peak selected from about 4.7, about 9.3, about 13.9, about 15.8, about 18.6, about 19.0, about 21.5, and about 27.4 degrees 2-theta.

9. The solid form of claim 6, wherein the solid form has at least three characteristic XRPD peak selected from about 4.7, about 9.3, about 13.9, about 15.8, about 18.6, about 19.0, about 21.5, and about 27.4 degrees 2-theta.

10. The solid form of claim 6, wherein the solid form has at least four characteristic XRPD peak selected from about 4.7, about 9.3, about 13.9, about 15.8, about 18.6, about 19.0, about 21.5, and about 27.4 degrees 2-theta.

11. The solid form of claim 6, having an XRPD pattern with characteristic peaks as substantially shown in Figure 1.

12. The solid form of any one of claims 6-11, exhibiting a DSC thermogram having endotherm peaks at temperatures of about 120 ºC and about 252 ºC.

13. The solid form of any one of claims 6-11, exhibiting a DSC thermogram having an endotherm peak at about 252 ºC.

14. The solid form of any one of claims 6-11, having a DSC thermogram substantially as depicted in Figure 2.

15. The solid form of any one of claims 6-14, having a thermogravimetric analysis ("TGA") thermogram substantially as depicted in Figure 3.

16. A process for preparing the solid form of any one of claims 6-15, comprising recrystallizing Compound 1 in DMSO, wherein the recrystallizing comprises heating a solution of Compound 1 in DMSO to a temperature that is greater than or equal to 90 ºC.

17. The process of claim 16, wherein the DMSO is substantially free of water.

18. The process of claim 16 or 17, wherein the process further comprises seeding the heated solution with Compound 1, Form A seeds, to form a seeded solution.

19. The process of claim 18, further comprising cooling the seeded solution.

20. A solid form prepared by the process of any one of claims 16 to 19.

21. The solid form of claim 5, wherein the solid form has Form B.

22. The solid form of claim 21, wherein the solid form has at least one characteristic XRPD peak selected from about 8.5, about 15.1, about 16.5, about 21.5, about 23.5, about 24.6, and about 25.5 degrees 2-theta.

23. The solid form of claim 21, wherein the solid form has at least two characteristic XRPD peaks selected from about 8.5, about 15.1, about 16.5, about 21.5, about 23.5, about 24.6, and about 25.5 degrees 2-theta.

24. The solid form of claim 21, wherein the solid form has at least one characteristic XRPD peak selected from about 8.5, about 15.1, about 23.5, and about 25.5 degrees 2-theta.

25. The solid form of claim 21, having an XRPD pattern with characteristic peaks as substantially shown in Figure 4.

26. The solid form of any one of claims 21-25, exhibiting a DSC thermogram having an endotherm peak at a temperatures of about 246 ºC.

27. The solid form of any one of claims 21-25, having a DSC thermogram substantially as depicted in Figure 5.

28. The solid form of any one of claims 21-27, having a thermogravimetric analysis ("TGA") thermogram substantially as depicted in Figure 6.

29. The solid form of any one of claims 21-28, having triclinic space group P1 and unit cell parameters: a = 6.43 Å; b = 8.37 Å; c = 20.95 Å; α = 89.7°; β = 82.0°; and γ = 69.6°.

30. A process for preparing the solid form of any one of claims 21-29, comprising recrystallizing Compound 1 in a mixture of water and acetic acid.

31. A solid form prepared by the process of claim 30.

32. The solid form of claim 5, wherein the solid form has Form C.

33. The solid form of claim 32, wherein the solid form has at least one characteristic XRPD peak selected from about 7.4, about 11.0, about 22.2, about 25.0, about 25.4, about 28.2, and about 29.8 degrees 2-theta.

34. The solid form of claim 32, wherein the solid form has at least two characteristic XRPD peaks selected from about 7.4, about 11.0, about 22.2, about 25.0, about 25.4, about 28.2, and about 29.8 degrees 2-theta.

35. The solid form of claim 32, wherein the solid form has at least one characteristic XRPD peak selected from about 7.4, about 22.2, about 25.0, about 25.4, and about 28.2 degrees 2-theta.

36. The solid form of claim 32, having an XRPD pattern with characteristic peaks as substantially shown in Figure 8.

37. The solid form of any one of claims 32-36, exhibiting a DSC thermogram having an exotherm peak at a temperature of about 242 ºC and an endotherm peak at a temperatures of about 253 ºC.

38. The solid form of any one of claims 32-36, having a DSC thermogram substantially as depicted in Figure 9.

39. The solid form of any one of claims 32-38, having a thermogravimetric analysis ("TGA") thermogram substantially as depicted in Figure 10.

40. A process for preparing the solid form of any one of claims 32-39, comprising recrystallizing Compound 1 in a solvent comprising DMSO.

41. A solid form prepared by the process of claim 40.

42. The solid form of claim 5, wherein the solid form has Form D.

43. The solid form of claim 42, having an XRPD pattern with characteristic peaks as substantially shown in Figure 11.

44. A process for preparing the solid form of claim 42 or 43, comprising recrystallizing Compound 1 in a solvent comprising dimethylacetamide.

45. A solid form prepared by the process of claim 44.

46. The solid form of claim 5, wherein the solid form has Form E.

47. The solid form of claim 46, wherein the solid form has at least one characteristic XRPD peak selected from about 8.7, about 15.3, about 16.2, about 18.3, about 23.2, about 25.5, and about 28.2 degrees 2-theta.

48. The solid form of claim 46, wherein the solid form has at least two characteristic XRPD peaks selected from about 8.7, about 15.3, about 16.2, about 18.3, about 23.2, about 25.5, and about 28.2 degrees 2-theta.

49. The solid form of claim 46, wherein the solid form has at least one characteristic XRPD peak selected from about 8.7, about 15.3, about 16.2, about 23.2, and about 25.5 degrees 2-theta.

50. The solid form of claim 46, having an XRPD pattern with characteristic peaks as substantially shown in Figure 12.

51. A process for preparing the solid form of any one of claim 46-50, comprising heating Compound 1 Form B to a temperature that is greater than or equal to 150 ºC.

52. A solid form prepared by the process of claim 51.

53. A pharmaceutical composition comprising a solid form of any one of claims 1-15, 20-29, 31-39, 41-43, 45-50, and 52, and at least one pharmaceutically acceptable carrier.

54. The solid form of any one of claims 1-15, 20-29, 31-39, 41-43, 45-50, and 52, or a pharmaceutically acceptable salt thereof, for use in therapy.

55. Use of the solid form of any one of claims 1-15, 20-29, 31-39, 41-43, 45-50, and 52, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a CNS disorder, wherein the solid form, or the pharmaceutically acceptable salt thereof, is to be contacted with an S1P receptor, and wherein the solid form, or the pharmaceutically acceptable salt thereof, is for modulating S1P receptor activity.

56. Use of the solid form of any one of claims 1-15, 20-29, 31-39, 41-43, 45-50, and 52, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder associated with S1P, wherein a therapeutically effective amount of the solid form, or the pharmaceutically acceptable salt thereof, is to be administered to a patient in need thereof.

57. Use of the solid form of any one of claims 1-15, 20-29, 31-39, 41-43, 45-50, and 52, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a CNS disorder in a patient in need thereof, wherein a therapeutically effective amount of the solid form, or the pharmaceutically acceptable salt thereof, is to be administered to the patient.